The laboratory offers in vitro tests for the identification of endocrine disruptors. These are tests to reveal interactions with hormone receptors (oestrogens and androgens) or with steroidogenesis: the H295R steroidogenesis test, the E-Screen test, the MDA-kb2 test and the YES and YAS tests.
The H295R steroidogenesis test is performed according to the OECD Test Guideline 456 on the human adrenal carcinoma cell line H295R and allows the detection of substances which influence, inducing or inhibiting, the production of testosterone and oestradiol.
The E-Screen test is a cell proliferation test using the human mammary carcinoma cell line MCF-7, the proliferation of which is oestrogen-dependent. This test makes it possible to demonstrate estrogenic or anti-estrogenic mechanisms.
The MDA-kb2 test is a transcriptional activation test involving the androgen receptor, carried out on the MDA-kb2 cell line. This is a test similar to the AR STTA test described in OECD Test Guideline No. 458, performed on another cell line. It demonstrates androgenic or anti-androgenic mechanisms linked to an interaction with the androgen receptor by means of the luciferase reporter gene.
The YES (Yeast Oestrogen Screen) and YAS (Yeast Androgen Screen) tests (XenoScreen XL YES YAS kit, Xenometrix), carried out on yeasts, can demonstrate agonist and/or antagonist mechanisms in estrogen and androgen receptors respectively, using the LacZ reporter gene coding for β-galactosidase.
Several additional tests are currently in development in the laboratory, in particular the AR STTA test (AR-EcoScreen cell line, OECD No. 458), the TA ER test (VM7-Luc-4E2 cell line, OECD No. 455) and tests for interactions with thyroid hormones.
If you would like to know more about our in vitro tests for the identification of endocrine disruptors, get in touch using the contact form below. We will get back to you as soon as possible.